MedCap (BATS-CHIXE:MCAPS) - Stock Price, News & Analysis

MCAPS Stock Overview

A private equity firm specializing in investments in secondary direct, later stage, industry consolidation, add-on acquisitions, growth capital, middle market, mature, turnarounds, buyout. More details

MCAPS fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	3/6
Financial Health	6/6
Dividends	0/6

Rewards

Price-To-Earnings ratio (30.2x) is below the Life Sciences industry average (39x)

Earnings grew by 21% over the past year

Risk Analysis

Shares are highly illiquid

MedCap AB (publ) Competitors

hVIVO

AIM:HVO

UK£146.3m

Ergomed

AIM:ERGO

UK£701.1m

C4X Discovery Holdings

AIM:C4XD

UK£30.3m

Bioventix

AIM:BVXP

UK£197.0m

Price History & Performance

Summary of all time highs, changes and price drops for MedCap
Historical stock prices
Current Share Price	SEK 272.00
52 Week High	SEK 272.00
52 Week Low	SEK 192.60
Beta	0.64
11 Month Change	0%
3 Month Change	2.06%
1 Year Change	n/a
33 Year Change	n/a
5 Year Change	n/a
Change since IPO	66.26%

Recent updates

Shareholder Returns

	MCAPS	GB Life Sciences	GB Market
7D	0%	11.4%	2.2%
1Y	n/a	-26.6%	9.0%

Return vs Industry: Insufficient data to determine how MCAPS performed against the UK Life Sciences industry.

Return vs Market: Insufficient data to determine how MCAPS performed against the UK Market.

Price Volatility

Is MCAPS's price volatile compared to industry and market?
MCAPS volatility
MCAPS Average Weekly Movement	n/a
Life Sciences Industry Average Movement	6.9%
Market Average Movement	4.8%
10% most volatile stocks in GB Market	10.3%
10% least volatile stocks in GB Market	2.6%

Stable Share Price: MCAPS has not had significant price volatility in the past 3 months.

Volatility Over Time: Insufficient data to determine MCAPS's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2001	478	Anders Dahlberg	medcap.se/en/

MedCap AB (publ) is a private equity firm specializing in investments in secondary direct, later stage, industry consolidation, growth capital, middle market, mature, turnarounds, buyout. It prefers to invest in healthcare equipment and services, biotechnology, life sciences, and pharmaceuticals companies. The firm prefers to invest in small to medium size companies that are not listed on the stock exchange and are based in Northern Europe.

MedCap AB (publ) Fundamentals Summary

How do MedCap's earnings and revenue compare to its market cap?
MCAPS fundamental statistics
Market cap	SEK 3.71b
Earnings (TTM)	SEK 122.80m
Revenue (TTM)	SEK 1.24b

30.2x

P/E Ratio

3.0x

P/S Ratio

Is MCAPS overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
MCAPS income statement (TTM)
Revenue	SEK 1.24b
Cost of Revenue	SEK 518.00m
Gross Profit	SEK 723.40m
Other Expenses	SEK 600.60m
Earnings	SEK 122.80m

Last Reported Earnings

Mar 31, 2023

Next Earnings Date

Jul 28, 2023

Earnings per share (EPS)	8.29
Gross Margin	58.27%
Net Profit Margin	9.89%
Debt/Equity Ratio	16.7%

How did MCAPS perform over the long term?

See historical performance and comparison